This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Merck Gets FDA Nod for Keytruda Use in Colorectal Cancer
by Zacks Equity Research
FDA approves Merck's (MRK) Keytruda for first-line treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer.
Merck (MRK) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Merck (MRK) closed at $76.12, marking a +1.24% move from the previous day.
Merck's Keytruda Wins FDA Nod for Squamous Cell Skin Cancer
by Zacks Equity Research
Merck's (MRK) sBLA for Keytruda for recurrent or metastatic cutaneous squamous cell carcinoma, a form of skin cancer, gets approval from the FDA.
Merck (MRK) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Merck (MRK) closed the most recent trading day at $77.12, moving +0.48% from the previous trading session.
Merck's Pneumococcal Vaccine Meets Goal in Two Adult Studies
by Zacks Equity Research
Merck's (MRK) development program on V114 comprises 16 studies, evaluating safety, tolerability and immunogenicity of V114 in a variety of patient populations.
Pfizer Begins Four Phase III Studies on Vaccine Candidates
by Zacks Equity Research
Pfizer (PFE) begins four phase III studies on vaccine candidates. EMA validates its label expansion application for Bavencio in first-line bladder cancer.
Agenus Stock Up on Licensing Deal With China-Based Firm
by Zacks Equity Research
Agenus (AGEN) signs an exclusive collaboration and license agreement with Chinese company, Betta Pharmaceuticals, for the development and commercialization of balstilimab and zalifrelimab.
Novo Nordisk Completes Two Studies on Obesity Candidate
by Zacks Equity Research
Novo Nordisk (NVO) provides data from a monotherapy study and a combination study on AM833.
Pharma Stock Roundup: FDA Approvals to MRK, LLY, NVS and GSK's Drugs
by Kinjel Shah
FDA approves expanded labels of Merck (MRK), Novartis (NVS) and Glaxo (GSK) drugs and Lilly's (LLY) new insulin.
Merck's Keytruda Gets Accelerated Approval for Solid Tumors
by Zacks Equity Research
Merck's (MRK) sBLA seeking approval of Keytruda for advanced solid tumors, based on biomarker, regardless of tumor type, gets FDA's accelerated approval.
Roche's Tecentriq With Chemotherapy Meets Goal for TNBC
by Zacks Equity Research
Roche's (RHHBY) phase III study evaluating the efficacy and safety of Tecentriq in combination with chemotherapy meets goal in early TNBC patients.
The Zacks Analyst Blog Highlights: Merck, CVS Health, Morgan Stanley, Applied Materials and Enterprise Products Partners
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Merck, CVS Health, Morgan Stanley, Applied Materials and Enterprise Products Partners
Merck (MRK) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Merck (MRK) closed at $76.29 in the latest trading session, marking a -0.88% move from the prior day.
Merck's Steglatro Non-Inferior in Cardiovascular Outcomes Study
by Zacks Equity Research
Merck's (MRK) type 2 diabetes drug, Steglatro, achieves primary endpoint of non-inferiority in major adverse CV events compared to placebo in a late-stage cardiovascular outcomes study.
Top Stock Reports for Merck, CVS & Morgan Stanley
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Merck (MRK), CVS Health (CVS) and Morgan Stanley (MS).
Bayer Initiates a Phase III Study in Heart Failure Patients
by Zacks Equity Research
Bayer (BAYRY) initiates a phase III study to evaluate finerenone compared to placebo in more than 5,500 symptomatic heart failure patients with a left ventricular ejection fraction.
Pharma Stock Roundup: Coronavirus Updates From ABBV, LLY, JNJ, FDA Approvals
by Kinjel Shah
J&J (JNJ), AbbVie (ABBV) and Lilly (LLY) make progress in coronavirus research efforts.
Novo Nordisk to Acquire Corvidia Therapeutics for $725M Cash
by Zacks Equity Research
Novo Nordisk (NVO) enters into a deal to acquire Corvidia Therapeutics for an upfront payment of $725 million in cash.
Bristol-Myers Gets FDA Nod for Label Expansion of Opdivo
by Zacks Equity Research
Bristol-Myers (BMY) gets FDA nod for Opdivo for the treatment of esophageal squamous cell carcinoma.
Clovis Completes Enrollment in Late-Stage Ovarian Cancer Study
by Zacks Equity Research
Clovis (CLVS) is developing Rubraca as monotherapy as well as in combination with Bristol-Myers' Opdivo as first-line maintenance treatment for ovarian cancer in the phase III ATHENA study.
Merck (MRK) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Merck (MRK) closed the most recent trading day at $81.77, moving -0.6% from the previous trading session.
Merck's Keytruda Fails in First-Line Bladder Cancer Study
by Zacks Equity Research
Merck's (MRK) phase III advanced bladder cancer study on Keytruda fails to meet dual primary endpoints of overall survival (OS) or progression-free survival (PFS).
Merck's Antibiotic Recarbrio Gets FDA Nod for New Indication
by Zacks Equity Research
The FDA approves Merck's (MRK) sNDA seeking approval for its antibacterial injection Recarbrio regarding a new indication. The application was filed in February 2020.
Bayer (BAYRY) Submits Applications for Heart Failure Drug
by Zacks Equity Research
Bayer (BAYRY) seeks approval of chronic heart failure drug, vericiguat, in the EU and Japan.
AstraZeneca to Ensure Equal Access to Coronavirus Vaccine
by Zacks Equity Research
AstraZeneca (AZN) signs three new supply deals to ensure broad and equitable global access to its COVID-19 vaccine following its successful development.